The Characterization and Evaluation of the Soluble Triggering Receptor Expressed on Myeloid Cells-like Transcript-1...

Area of Science:

• Biochemistry
• Cardiology
• Immunology

Background:

• Platelets are key in coronary artery disease (CAD) progression.
• Soluble triggering receptor expressed in myeloid cells-like transcript-1 (sTLT-1), released from activated platelets, is a potential biomarker.
• Understanding sTLT-1's characteristics and role in CAD is crucial.

Purpose of the Study:

• To characterize sTLT-1's amino acid composition.
• To evaluate sTLT-1 as a biomarker in stable coronary artery disease (CAD) patients.
• To investigate the association between sTLT-1 levels and clinical outcomes in CAD.

Main Methods:

• Immunoprecipitation and mass spectrometry were used to identify sTLT-1 residues and cleavage sites.
• ELISA measured plasma sTLT-1 concentrations in 1510 stable CAD patients.
• Statistical analyses correlated sTLT-1 levels with clinical outcomes, including left ventricular (LV) function and major cardiac events.

Main Results:

• TLT-1 residues up to 133 were identified; ADAM17 cleavage suggests S136 as the C-terminal amino acid of sTLT-1.
• No significant difference in sTLT-1 levels was observed for primary outcomes (death, major cardiac event).
• CAD patients with LV dysfunction showed significantly lower sTLT-1 levels compared to those with normal LV function (p=0.003).
• Lower sTLT-1 levels (below 544 pg/mL) were significantly associated with congestive heart failure (OR=2.94, p=0.042), potentially due to LV dysfunction.

Conclusions:

• sTLT-1 characterization provides insights into its structure and release mechanism.
• Plasma sTLT-1 levels do not predict major adverse cardiac events in stable CAD.
• Reduced sTLT-1 levels are linked to LV dysfunction and congestive heart failure in CAD patients, indicating potential as a biomarker for these conditions.